Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be improved upon. In this interview, Giovanni Martinelli, MD, of the Istituto Scientifico Romagnolo, Meldola, Italy, talks about a recently developed drug, blinatumomab. While the data from the current clinical trial, D-ALBA (NCT02744768), has only recently become available, Prof. Martinelli is hopeful enfor this treatment. This interview took place at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
Promising outlook for frontline blinatumomab in Ph+ ALL
